Skip to content

Debt-to-equity at other companies

Boston Scientific logo
Boston ScientificBSX
-0.5×
AngioDynamics logo
AngioDynamicsANGO
0.0×
Delcath Systems logo
Delcath SystemsDCTH
0.0×
Tactile Systems Technology logo
Tactile Systems TechnologyTCMD
0.1×-0.1×
LQD
Liquidia CorporationLQDA
0.1×-0.1×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
0.0×

Other financials

Income statement

See full
Revenue$8.9M-2.9%
Gross profit$7.7M0.0%
Operating income-$8.4M-14.8%
Net income$1.5M+115%
EPS (diluted)$0.03+108%

Balance sheet

See full
Cash & equivalents$56.6M+324%
Total debt$33.1M+4.4%
Total equity$12.8M+137%
Total assets$71.0M+148%

Cash flow

See full
Operating cash flow-$6.5M-44.0%
CapEx$141.0K-81.3%
Free cash flow-$6.6M-26.0%

Valuation

See full
Market cap$279.45M+49.6%
Enterprise value$255.97M+33.6%
P/S6.2×+1.0×

Profitability

See full
Gross margin85.1%-0.5pp
Operating margin-62.4%-16.8pp
Net margin-60.9%-13.4pp
FCF margin-45.2%-16.8pp

Returns & leverage

See full
Return on equity253.3%
Current ratio5.8×+3.6×

Where this comes from

Calculated from TriSalus Life Sciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about TriSalus Life Sciences, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TriSalus Life Sciences, Inc.'s debt-to-equity?
TriSalus Life Sciences, Inc. (TLSI) reported debt-to-equity of 2.6× in Q1 2026.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.